Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd. announced that FL115 subcutaneous injection (administered once every three weeks)...
ForLong Biotechnology
Suzhou Forlong Biotech, Shanghai Henlius, and Engineered Cytokine Immunotherapy Collaboration Announced
Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc....
Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...
Forlong Biotechnology Secures Series A Funding for Protein Drug Development
Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...